U.S. Tardive Dyskinesia Treatment Market to Reach USD 6417.43 Million by 2031 at 9.8% CAGR; North America Leads with 46% Share - Key Players: Teva, Neurocrine Biosciences, Lupin

The U.S. Tardive Dyskinesia Treatment Market was valued at USD 3061.64 million in 2023 and is projected to reach USD 6417.43 million by 2031, reflecting a CAGR of 9.8 percent during the forecast period. Tardive dyskinesia is a neurological condition characterized by involuntary, repetitive body movements that commonly arise after long-term use of certain medications, especially antipsychotics prescribed for conditions such as schizophrenia and bipolar disorder. Symptoms may include facial grimacing, tongue movements, lip smacking, pursed lips and rapid eye blinking, and in some cases, rapid movements of the limbs or torso. The increasing prevalence of psychiatric disorders and growing awareness of the side effects associated with prolonged antipsychotic therapy are supporting the continued expansion of the treatment market.

Management of tardive dyskinesia typically involves adjusting or tapering the medications that trigger symptoms, with close medical supervision to prevent exacerbation of the underlying condition. Alternative therapies with a lower risk profile, including certain atypical antipsychotics, may also be considered. Supportive care such as physical therapy, speech therapy and occupational therapy helps improve daily functioning and alleviate the impact of motor symptoms. Lifestyle strategies, including stress reduction and nutritional support, further contribute to better symptom control. These combined approaches are strengthening demand for effective tardive dyskinesia treatments across the U.S. healthcare system.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/us-tardive-dyskinesia-treatment-market?sai-v

The Tardive Dyskinesia Treatment Market refers to the industry focused on therapies and drugs designed to manage and reduce involuntary, repetitive movements caused by long-term use of antipsychotic medications.

Key Developments
✅ October 2025: Leading pharmaceutical companies expanded late-stage clinical evaluations of VMAT2 inhibitors, focusing on long-term safety profiles and real-world patient adherence in tardive dyskinesia management.

✅ September 2025: Healthcare networks in North America deployed AI-supported motor-symptom recognition tools in psychiatric settings to improve early detection of tardive dyskinesia among patients on chronic antipsychotics.

✅ August 2025: Biotech firms advanced extended-release formulations of TD therapies designed to reduce dosing frequency and improve caregiver and patient convenience.

❇️ July 2025: Research institutions launched multi-regional clinical trials testing adjunctive therapies that combine VMAT2 inhibitors with neuroprotective compounds for treatment-resistant TD populations.

✅ May 2025: European mental health authorities strengthened awareness programs targeting earlier identification of drug-induced movement disorders within long-term psychiatric care environments.

✅ March 2025: Asia-Pacific hospitals expanded the use of digital neurological assessment platforms to support continuous monitoring of involuntary movements in patients receiving antipsychotic medications.

Mergers & Acquisitions
❇️ November 2025: A global neuroscience-focused pharmaceutical company acquired a biotech developer of novel VMAT-modulating candidates to broaden its portfolio in advanced TD therapeutics.

✅ August 2025: A major European pharmaceutical company entered a strategic partnership with a North American digital health firm to co-create AI-driven monitoring tools for tardive dyskinesia symptom tracking.

✅ June 2025: A leading specialty-care drug manufacturer acquired a movement-analysis technology startup to integrate precision motor-tracking capabilities into future TD treatment platforms.

Key Players
Teva Pharmaceutical Industries Ltd. | Neurocrine Biosciences, Inc. | Lupin Limited | Accord Healthcare, Inc. | Mitsubishi Corporation | Dr. Reddy's Laboratories Limited | BIONPHARMA Inc. | Slate Run Pharmaceuticals | Aurobindo Pharma Limited | Apotex Inc.

Key Highlights
Teva Pharmaceutical Industries Ltd. - Holds an estimated 19.4% share, driven by its strong generics leadership, extensive neurological disorder portfolio, and global distribution capabilities.

Neurocrine Biosciences, Inc. - Accounts for around 14.6% share, supported by its innovative CNS therapies, including breakthrough treatments for movement disorders and psychiatric conditions.

Lupin Limited - Maintains approximately 9.8% share, fueled by its expanding generics portfolio, strong regulatory approvals, and growing presence in the U.S. neurology and psychiatry markets.

Accord Healthcare, Inc. - Represents nearly 7.1% share, recognized for its broad injectable and oral generics lineup, competitive pricing, and strong penetration in North American and European markets.

Mitsubishi Corporation - Holds about 6.4% share, driven by strategic partnerships, investments in specialty pharmaceuticals, and participation in high-value CNS therapy markets.

Dr. Reddy's Laboratories Limited - Accounts for around 10.2% share, supported by its robust API expertise, cost-efficient generics production, and expanding pipeline for neurological disease treatments.

BIONPHARMA Inc. - Maintains roughly 5.3% share, strengthened by niche generic launches, focus on U.S. prescription markets, and agile product development capabilities.

Slate Run Pharmaceuticals - Represents approximately 3.8% share, driven by specialty generics targeting CNS and chronic care segments with consistent market uptake.

Aurobindo Pharma Limited - Holds an estimated 12.1% share, fueled by its extensive generics footprint, large-scale manufacturing capabilities, and strong presence in regulated markets such as the U.S. and Europe.

Apotex Inc. - Accounts for around 11.3% share, known for its broad generic pharmaceuticals portfolio, strong global distribution network, and growing CNS-related product offerings.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=us-tardive-dyskinesia-treatment-market?sai-v

Market Drivers

- Rising prevalence of tardive dyskinesia linked to long-term antipsychotic medication use for conditions such as schizophrenia, bipolar disorder, and major depression.

- Increasing awareness and early diagnosis of TD encouraging timely treatment interventions.

- Growing adoption of VMAT2 inhibitors as first-line therapy due to proven efficacy in reducing involuntary movements.

- Expanding mental health treatment rates globally increasing the population at risk for TD.

- Advancements in neurological research supporting the development of targeted therapies for movement disorders.

- Increasing healthcare spending and improved access to psychiatric and neurological care in emerging regions.

- Rising focus on improving patient quality of life driving demand for safe and effective long-term TD treatments.

Industry Developments

- Launch of next-generation VMAT2 inhibitors offering improved dosing convenience and reduced side effects.

- Strategic collaborations between pharmaceutical companies and neurology research institutions to advance TD drug development.

- Expansion of clinical trials evaluating novel mechanisms of action for movement disorder control.

- Increased investment in real-world evidence (RWE) studies to assess long-term safety and efficacy of TD treatments.

- Development of digital health tools and symptom-tracking applications supporting continuous TD monitoring.

- Growing availability of patient support programs improving access and adherence to TD medications.

Regional Insights

North America - 46% share: "Driven by high antipsychotic prescription rates, strong availability of VMAT2 inhibitors, and advanced neurological care infrastructure."

Europe - 30% share: "Supported by increasing mental health treatment accessibility, rising TD diagnosis rates, and expanding adoption of evidence-based therapies."

Asia Pacific - 18% share: "Fueled by growing psychiatric medicine usage, increasing awareness of movement disorders, and improving healthcare infrastructure."

Latin America - 4% share: "Boosted by gradual expansion of neurology services, rising mental health treatment rates, and improved drug accessibility."

Middle East & Africa - 2% share: "Driven by rising focus on mental health, improving diagnostic capabilities, and slow but growing adoption of specialized TD treatments."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/us-tardive-dyskinesia-treatment-market?sai-v

Key Segments

➥ By Drug
• Valbenazine: A VMAT2 inhibitor widely used for managing tardive dyskinesia, offering improved symptom control with a favorable safety profile.
• Deutetrabenazine: Provides enhanced bioavailability and reduced dosing frequency, helping effectively treat movement disorders such as tardive dyskinesia and Huntington's-related chorea.
• Tetrabenazine: A long-established VMAT2 inhibitor used to manage hyperkinetic movement disorders, though often associated with higher side-effect potential compared to newer alternatives.
• Clonazepam: A benzodiazepine used to reduce involuntary movements by enhancing GABA activity, commonly prescribed for short-term or adjunctive symptom relief.
• Amantadine: Offers dopaminergic and antiglutamatergic effects, supporting symptom management in certain movement disorders.
• Others: Includes off-label therapies and supportive medications used based on patient needs and clinician preferences.

➥ By Distribution Channel
• Hospital and Specialty Pharmacies: Provide access to prescription-based movement disorder medications, especially for patients requiring specialized care, monitoring, and dosage adjustments.
• Retail Pharmacies: Facilitate broad availability of prescribed drugs, improving patient convenience, refills, and adherence support.
• Others: Includes online pharmacies and mail-order channels offering flexible access and home-delivery options for chronic therapy management.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.